智通财经APP讯，康基医疗(09997)发布公告，于2025年8月13日上午9时正起恢复买卖。 ...

Group 1 - The company Kangji Medical (09997) announced that trading will resume on August 13, 2025, at 9:00 AM [1]

Core Viewpoint - Kangji Medical (09997.HK) announced that its shares will resume trading starting at 9:00 AM on August 13, 2025 [1] Company Summary - The company has made an official announcement regarding the resumption of its stock trading [1]

Group 1 - The core proposal involves privatizing 康基医疗 (09997) through an agreement under Section 86 of the Companies Ordinance, with the offeror Knight Bidco Limited seeking to present this to shareholders [1] - Upon completion of the proposal, 康基医疗 will become a wholly-owned subsidiary of the offeror, and its shares will be delisted from the Hong Kong Stock Exchange [1] - The proposed cash consideration for shareholders is HKD 9.25 per share, representing a premium of approximately 9.9% over the last closing price of HKD 8.42 [1] Group 2 - The offeror is fully owned by MidCo, which in turn is wholly owned by TopCo, with TopCo being held by a consortium of members [1] - The consortium members hold the following approximate stakes: Fortune Spring ZM (25.53%), Fortune Spring YG (14.47%), TPG Asia VII (24.38%), Keyhole (5.01%), Knight Success (5.69%), NewQuest V (4.56%), and Al-Rayyan Holding (20.36%) [1]

Major Events - Kangji Medical (09997) received a privatization offer at a premium of approximately 9.9% [1] - China Resources Pharmaceutical (03320) plans to participate in the establishment of a fund [1] - Ganfeng Lithium (01772) intends to jointly integrate a joint venture with LAR to develop the Pozuelos-Pastos Grandes salt lake basin in Argentina [1] - China Antibody-B (03681) signed a comprehensive strategic cooperation agreement with the Hong Kong Advanced Institute of Research at Sun Yat-sen University [1] - Mingyuan Cloud (00909) plans to acquire 100% equity of ASIOT Corporation for 700 million yen [1] - Weilu Group (01196) experienced unusual stock price and trading volume changes and is in preliminary discussions with an independent third party regarding a potential acquisition of mobile game rights [1] Operating Performance - China Unicom (00762) reported revenue exceeding 200 billion yuan in the first half of the year, with a profit attributable to equity holders of 14.484 billion yuan, a year-on-year increase of 5.01% [1] - China Unicom (00762) had approximately 1.208 billion cumulative "Ubiquitous Intelligent Connection" users in the second quarter [1] - Tencent Music (01698) achieved double growth in revenue and profit in the first half of the year, with a profit attributable to equity holders of 6.7 billion yuan, a year-on-year increase of 115.85% [1] - Galaxy Entertainment (00027) reported a mid-term profit attributable to shareholders of 5.24 billion HKD, a year-on-year increase of 19.44% [1] - WH Group (00288) reported a mid-term profit attributable to shareholders of 788 million USD, a year-on-year increase of 0.51%, with an interim dividend of 0.2 HKD per share [1] - Minmetals Resources (01208) reported a mid-term profit attributable to equity holders of 340 million USD, a year-on-year increase of 1511% [1] - China Literature Group (00772) reported a mid-term profit attributable to shareholders of 850 million yuan, a year-on-year increase of 68.5% [1] - Hong Kong Electric (02638) reported a mid-term profit attributable to unit holders of 1.001 billion HKD, a year-on-year increase of 5.7% [1] - 361 Degrees (01361) reported a mid-term profit attributable to equity holders of 858 million yuan, a year-on-year increase of 8.6% [1] - Eagle Precision (01286) reported a mid-term profit attributable to equity holders of 346 million HKD, a year-on-year increase of 13.7% [1] - China Everbright Water (01857) reported a mid-term profit attributable to equity holders of 564 million HKD, a year-on-year decrease of 2.99% [1] - FIT HON TENG (06088) reported a mid-term profit attributable to shareholders of 31.511 million USD, a year-on-year decrease of 3.11% [1] - China Lilang (01234) reported a mid-term profit attributable to equity holders of 243 million yuan, a year-on-year decrease of 13.4% [1] - Fudan Zhangjiang (01349) reported a mid-term profit attributable to shareholders of 5.715 million yuan, a year-on-year decrease of 91.89% [1] - Wharf Holdings (00004) reported a mid-term profit attributable to shareholders of 535 million HKD, returning to profitability [1] - China Resources Land (01109) reported a cumulative contract sales amount of approximately 123.6 billion yuan for the first seven months, a year-on-year decrease of 11.8% [1]

Core Viewpoint - 康基医疗 (09997.HK) is proposing to privatize the company through an agreement under Section 86 of the Companies Ordinance, with Knight Bidco Limited as the offeror [1] Group 1: Privatization Proposal - The proposal involves the company becoming a wholly-owned subsidiary of Knight Bidco Limited, leading to the delisting of its shares from the Hong Kong Stock Exchange [1] - The cancellation price is set at HKD 9.25 per share, representing a premium of approximately 9.9% over the last trading price of HKD 8.42 [1] - The board will appoint an independent financial advisor to provide opinions to the independent board committee regarding the proposal [1] Group 2: Financial and Operational Context - The company faces challenges in raising funds from the equity market due to ongoing pressure on transaction prices and limited liquidity of its shares [1] - Considering the costs associated with being listed, the company believes that maintaining its listing status offers limited benefits [1] - Implementing the privatization proposal is expected to alleviate short-term financial performance pressures and allow the company to focus on strategic goals requiring additional resource allocation for sustainable future growth [1] Group 3: Trading Resumption - The company has applied for the resumption of trading of its shares on the Hong Kong Stock Exchange starting from 9:00 AM on August 13, 2025 [1]

在满足先决条件后，该建议将通过该计划实施。根据该计划，计划股份将被注销，而计划股东(不包括 创始人计划股份及TPG计划股份的持有人)将就每股计划股份获得现金9.25港元，注销价格9.25港元较股 份于最后交易日在联交所所报的收市价每股8.42港元溢价约9.9%。 于公告日期，要约人由MidCo全资拥有，而MidCo由TopCo全资拥有。于本公告日期，TopCo由财团成 员持有，其中Fortune Spring ZM、Fortune Spring YG、TPG Asia VII、Keyhole、Knight Success、 NewQuest V及Al-Rayyan Holding分别持有约25.53%、约14.47%、约24.38%、约5.01%、约5.69%、约 4.56%及约20.36%。 智通财经APP讯，康基医疗(09997)及要约人Knight Bidco Limited联合公布，于2025年7月17日，要约人 要求董事会向股东提呈该建议，内容有关建议根据公司法第86条以协议安排方式将该公司私有化。于该 建议完成后，该公司将成为要约人的全资附属公司，而股份于联交所的上市地位将被撤销。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內 容 概 不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不對因本公告全部或任何部份內容而產生或因倚賴該等內容而引致的 任 何 損 失 承 擔 任 何 責 任。 本 公 告 僅 供 參 考，並 不 旨 在 亦 不 構 成 購 買 或 認 購 或 邀 請 購 買 或 認 購 要 約 人 或 本 公 司 任 何 證 券 的 任 何 要 約 或 成 為 其 一 部 份，亦 非 於 任 何 司 法 權 區 徵 求 任 何 投 票 或 批 准。 本公告 的全部或部份內容不會在 違 反 任 何 司法管轄區適用法律或法規 之司法管轄區 內 刊 發、登 載 或 派 發。 KNIGHT BIDCO LIMITED （於 開 曼 群 島 註 冊 成 立 之 有 限 公 司） Kangji Medical Holdings Limited （於開曼群島註冊成立的有限公司） 康基医疗控股有限公司 聯合公告 有 關 (1)要約人根據開曼群島公司法第86條通過協議安排將 康 基 醫 療 控股有限公司 私有化之附帶先決條件的 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年7月31日 狀態: 新提交 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 09997 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 5,000,000,000 | USD | | 0.00001 | USD | | 50,000 | | 增加 / 減少 (-) | | | | | | | USD | | | | 本月底結存 | | | 5,000,000,000 | USD | | 0.00001 | USD | | 50,000 | 本月底法定/註冊股本總額： USD 50,000 FF301 第 1 頁 共 10 頁 v 1.1.1 FF301 II ...

Core Insights - The National Medical Products Administration (NMPA) has announced measures to optimize the lifecycle regulation of high-end medical devices, focusing on areas such as medical robots, high-end medical imaging equipment, AI medical devices, and new biological materials [1] - The global high-end medical device market is projected to exceed $1.8 trillion by 2030, with China's market expected to reach 2.8 trillion RMB [1] Industry Focus Areas - **Brain-Computer Interface (BCI)**: The BCI market in China is expected to reach 3.2 billion RMB in 2024, growing at 18.8%, and is projected to reach 5.58 billion RMB by 2027 with a growth rate of 20%. Challenges include technical bottlenecks and ethical controversies [2] - **High-End Medical Imaging Equipment**: The domestic market has seen rapid development, with increasing localization in mid-to-low-end products. However, high-end imaging equipment still faces challenges, particularly in the localization of key components [2] - **Surgical Robots**: The market for surgical robots is dominated by laparoscopic surgical robots, with the Da Vinci system currently leading. Domestic products are entering the market, which may disrupt the current landscape [3] - **High-Value Consumables**: These account for about 20% of the medical device market. While some segments have achieved domestic substitution, others, particularly in cardiac and neurological devices, still rely heavily on imports [3] - **In Vitro Diagnostics (IVD)**: The IVD industry has seen significant domestic advancement in low-end technologies, but high-end segments remain largely dominated by foreign brands [3] Market Trends - The medical device industry is characterized by a dual focus on technology-driven innovation and domestic substitution. Key components for high-end devices are being developed domestically, with some products nearing international standards [4] Related Companies - **MicroPort Scientific Corporation (微创机器人)**: Reported over 130 core product orders, with significant growth in laparoscopic surgical robots [5] - **Yimai Sunshine (一脉阳光)**: Engaged in building medical imaging centers and has launched an AI medical imaging model, marking a transition in the industry [6] - **Yongsheng Medical (永胜医疗)**: Focuses on rehabilitation robotics and has secured agreements for health care product procurement [6] - **Kangji Medical (康基医疗)**: Recently received regulatory approval for a four-arm laparoscopic surgical robot, expanding its clinical application range [7]